Stapled truncated orexin peptides as orexin receptor agonists
- Peptides. 2018 Apr;102:54-60. doi: 10.1016/j.peptides.2018.02.004.
- 1. Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, POB 56, FI-00014 University of Helsinki, Finland. Electronic address: [email protected].
- 2. School of Pharmacy, University of Eastern Finland, POB 1627, FI-70211 Kuopio, Finland. Electronic address: [email protected].
- 3. Biochemistry and Cell Biology, Department of Veterinary Biosciences, Faculty of Veterinary Medicine, POB 66, FI-00014, University of Helsinki, Finland; Department of Physiology, Institute of Biomedicine, Biomedicum Helsinki, POB 63, FI-00014 University of Helsinki, Finland. Electronic address: [email protected].
- 4. Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, POB 56, FI-00014 University of Helsinki, Finland. Electronic address: [email protected].
- 5. Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, POB 56, FI-00014 University of Helsinki, Finland. Electronic address: [email protected].
- 6. Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, POB 56, FI-00014 University of Helsinki, Finland. Electronic address: [email protected].
- 7. Biochemistry and Cell Biology, Department of Veterinary Biosciences, Faculty of Veterinary Medicine, POB 66, FI-00014, University of Helsinki, Finland; Department of Physiology, Institute of Biomedicine, Biomedicum Helsinki, POB 63, FI-00014 University of Helsinki, Finland. Electronic address: [email protected].
- 8. Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, POB 56, FI-00014 University of Helsinki, Finland. Electronic address: [email protected].
The peptides orexin-A and -B, the endogenous agonists of the orexin receptors, have similar 19-amino-acid C-termini which retain full maximum response as truncated peptides with only marginally reduced potency, while further N-terminal truncations successively reduce the activity. The peptides have been suggested to bind in an α-helical conformation, and truncation beyond a certain critical length is likely to disrupt the overall helical structure. In this study, we set out to stabilize the α-helical conformation of orexin-A15-33 via peptide stapling at four different sites. At a suggested hinge region, we varied the length of the cross-linker as well as replaced the staple with two α-aminoisobutyric acid residues. Modifications close to the peptide C-terminus, which is crucial for activity, were not allowed. However, central and N-terminal modifications yielded bioactive peptides, albeit with decreased potencies. This provides evidence that the orexin receptors can accommodate and be activated by α-helical peptides. The decrease in potency is likely linked to a stabilization of suboptimal peptide conformation or blocking of peptide backbone-receptor interactions at the hinge region by the helical stabilization or the modified Amino acids.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Amino Acid DerivativesResearch Areas: Others